WO2014080309A3 - Compositions and methods for the treatment of inflammation and lipid disorders - Google Patents

Compositions and methods for the treatment of inflammation and lipid disorders Download PDF

Info

Publication number
WO2014080309A3
WO2014080309A3 PCT/IB2013/059867 IB2013059867W WO2014080309A3 WO 2014080309 A3 WO2014080309 A3 WO 2014080309A3 IB 2013059867 W IB2013059867 W IB 2013059867W WO 2014080309 A3 WO2014080309 A3 WO 2014080309A3
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compositions
treatment
methods
lipid disorders
Prior art date
Application number
PCT/IB2013/059867
Other languages
French (fr)
Other versions
WO2014080309A2 (en
Inventor
Mahesh Kandula
Original Assignee
Mahesh Kandula
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mahesh Kandula filed Critical Mahesh Kandula
Publication of WO2014080309A2 publication Critical patent/WO2014080309A2/en
Publication of WO2014080309A3 publication Critical patent/WO2014080309A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/40—Y being a hydrogen or a carbon atom
    • C07C323/41—Y being a hydrogen or an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3

Abstract

The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II; and methods for treating or preventing inflammation and lipid disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of hypertriglyceridemia, neurodegenerative diseases and bowel diseases.
PCT/IB2013/059867 2012-11-21 2013-11-03 Compositions and methods for the treatment of inflammation and lipid disorders WO2014080309A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN4863CH2012 2012-11-21
IN4863/CHE/2012 2012-11-21

Publications (2)

Publication Number Publication Date
WO2014080309A2 WO2014080309A2 (en) 2014-05-30
WO2014080309A3 true WO2014080309A3 (en) 2014-12-24

Family

ID=50776624

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/059867 WO2014080309A2 (en) 2012-11-21 2013-11-03 Compositions and methods for the treatment of inflammation and lipid disorders

Country Status (1)

Country Link
WO (1) WO2014080309A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2692895A (en) * 1950-08-23 1954-10-26 Opfermann Adolf Christia Josef Production of pantothenaldehyde and acetals thereof
EP0421441A2 (en) * 1989-10-06 1991-04-10 Fujirebio Inc. Pantothenic acid derivatives
WO1995011884A1 (en) * 1993-10-27 1995-05-04 Oculon Corporation Compounds and methods for inhibiting cataract formation
US20030153788A1 (en) * 2000-06-30 2003-08-14 Seikagaku Corporation Epoxycarboxamide compound, azide compound, and amino alcohol compound, and process for preparing alpha-keto amide compound using them
WO2011152721A1 (en) * 2010-05-31 2011-12-08 Umc St. Radboud Derivatives of pantothenic acid and their use for the treatment of malaria

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2692895A (en) * 1950-08-23 1954-10-26 Opfermann Adolf Christia Josef Production of pantothenaldehyde and acetals thereof
EP0421441A2 (en) * 1989-10-06 1991-04-10 Fujirebio Inc. Pantothenic acid derivatives
WO1995011884A1 (en) * 1993-10-27 1995-05-04 Oculon Corporation Compounds and methods for inhibiting cataract formation
US20030153788A1 (en) * 2000-06-30 2003-08-14 Seikagaku Corporation Epoxycarboxamide compound, azide compound, and amino alcohol compound, and process for preparing alpha-keto amide compound using them
WO2011152721A1 (en) * 2010-05-31 2011-12-08 Umc St. Radboud Derivatives of pantothenic acid and their use for the treatment of malaria

Also Published As

Publication number Publication date
WO2014080309A2 (en) 2014-05-30

Similar Documents

Publication Publication Date Title
WO2013175377A3 (en) Compositions and methods for treatment of mucositis
WO2013175376A3 (en) Compositions and methods for the treatment of local pain
GEP20135806B (en) Lactams as beta secretase inhibitors
WO2014174425A3 (en) Compositions and methods for the treatment of orthostasis and neurological diseases
WO2014068463A3 (en) Compositions and methods for the treatment of inflammation and metabolic disorders
WO2016046680A3 (en) Compositions and methods for the treatment of liver metabolic diseases
WO2013175359A3 (en) Compositions and methods for the treatment of multiple sclerosis
MX2019003912A (en) Compositions and methods for the treatment of xerostomia.
WO2014087307A3 (en) Compositions and methods for the treatment of metabolic syndrome and diabetes
WO2014091384A3 (en) Compositions and methods for the treatment of mucositis
MX2019000279A (en) Compositions and methods for the treatment of cancer.
MX2022005523A (en) Compositions and methods for the treatment of fungal infections.
WO2014006529A3 (en) Compositions and methods for the treatment of moderate to severe pain
WO2014087323A3 (en) Compounds and compositions for the treatment of autoimmune and chronic metabolic diseases
MX2019006163A (en) Compositions and methods for the treatment of oral infectious diseases.
WO2014097137A3 (en) Compositions and methods for the treatment of seizures and neurologic diseases
WO2014106804A3 (en) Compositions and methods for the treatment of metabolic syndrome and diabetes
WO2013167989A3 (en) Compositions and methods for the treatment of neurological disorders
MX2019005568A (en) Compositions and methods for the treatment of gastrointestinal polyps.
WO2013175344A3 (en) Compositions and methods for treatment of peridontitis and rheumatoid arthritis
WO2015028976A3 (en) Compounds and methods for the treatment of inflammatory diseases
WO2014037834A3 (en) Compositions and methods for treatment of inflammation and lipid disorders
WO2014080309A3 (en) Compositions and methods for the treatment of inflammation and lipid disorders
WO2014068461A3 (en) Compositions and methods for the treatment of acute inflammation
WO2014037833A3 (en) Compositions and methods for treatment of inflammation and lipid disorders

Legal Events

Date Code Title Description
122 Ep: pct application non-entry in european phase

Ref document number: 13857457

Country of ref document: EP

Kind code of ref document: A2